AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +65

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

📅 AbbVie is presenting new data at the European Hematology Association (EHA) 2026 Congress in Stockholm on June 8, 2026.

🔬 Six oral presentations and multiple posters highlight advancements across six blood cancer types: MM, FL, CLL, DLBCL, AML, and amyloidosis.

💊 Approved therapies featured include EPKINLY (epcoritamab-bysp), VENCLEXTA (venetoclax), and DECNUPAZ (pivekimab sunirine-pvzy).

📈 EPCORE FL-1 trial subgroup analysis shows numerically higher overall response rates for epcoritamab + lenalidomide + rituximab vs. standard care in high-risk follicular lymphoma patients.

⚖️ EPCORE DLBCL-1 trial results show statistically significant improvement in progression-free survival (30% vs 13% at 24 months) for epcoritamab monotherapy versus chemoimmunotherapy.

🦠 Higher rates of grade 3–4 infections (30% vs 12%) and COVID-19 (36% vs 11%) were reported in the epcoritamab arm of the DLBCL trial.

🧬 GAIA/CLL13 trial results predict efficacy of venetoclax-based therapies in previously untreated CLL patients lacking specific genetic mutations.

🔍 REVIVE study examines real-world management practices with venetoclax-based therapy for newly diagnosed AML patients unfit for intensive chemotherapy.

🧪 MONVISO study evaluates etentamig in relapsed/refractory multiple myeloma patients with prior BCMA-targeted therapy exposure.

🩺 Updated results from M24-209 show longer-term safety and efficacy of etentamig monotherapy in light chain amyloidosis.

🧬 CADENZA study presents post-hoc analysis of pivekimab sunirine-pvzy efficacy in blastic plasmacytoid dendritic cell neoplasm with skin involvement.

🤝 EPKINLY is co-developed by Genmab and AbbVie, with AbbVie responsible for global commercialization outside the U.S. and Japan.

⚠️ Important safety warnings include cytokine release syndrome, neurologic problems, infections, and low blood cell counts for epcoritamab.

🛡️ VENCLEXTA carries risks of tumor lysis syndrome, requiring specific hydration protocols and monitoring before and during treatment.

📊 Full abstracts and details on key presentations are available via the provided links in the press release.

Bullish Signals
  • EPCORE FL-1 trial subgroup analysis demonstrates numerically higher overall response rates (96.5% vs 84.8% in low-risk; 93.0% vs 72.6% in high-risk) for epcoritamab combination therapy compared to standard care.
  • EPCORE DLBCL-1 trial shows statistically significant improvement in progression-free survival with epcoritamab monotherapy (HR 0.74), achieving 30% 24-month PFS versus 13% for chemoimmunotherapy.
  • No new safety signals were observed across subgroups in the EPCORE FL-1 trial, indicating consistent tolerability of the epcoritamab combination therapy.
  • Venetoclax-based therapies show predicted efficacy in CLL patients based on genetic biomarkers, offering potential for personalized treatment approaches.
  • Real-world data from the REVIVE study provides insights into managing venetoclax-based therapy for AML patients who cannot tolerate intensive chemotherapy.
  • Etentamig shows promise in relapsed/refractory multiple myeloma even after prior exposure to BCMA-targeted therapies, addressing a critical unmet need.
  • Longer-term safety and efficacy data for etentamig in amyloidosis supports its potential as a durable treatment option for this rare disease.
  • AbbVie's robust pipeline includes more than 35 investigational medicines across blood cancers and solid tumors, demonstrating strong R&D commitment.
Risk Factors
  • EPCORE DLBCL-1 trial did not demonstrate a statistically significant improvement in overall survival for epcoritamab monotherapy versus chemoimmunotherapy.
  • Higher rates of grade 3–4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%) were reported in the epcoritamab arm of the DLBCL trial.
  • Grade 5 treatment-emergent adverse events occurred more frequently in the epcoritamab arm (17% vs 6%), largely attributable to severe COVID-19 cases.
  • EPKINLY carries serious safety risks including cytokine release syndrome, neurologic problems, and infections that may lead to hospitalization or death.
  • VENCLEXTA poses a risk of tumor lysis syndrome, which can cause kidney failure and requires strict hydration and monitoring protocols.
  • Etentamig and pivekimab sunirine-pvzy are investigational therapies not approved in the EU, limiting immediate market access for these candidates.
  • Safety warnings for EPKINLY include risks of CRS and neurologic problems that may require step-up dosing schedules and hospitalization on Day 15 or 22 of Cycle 1.
Full Analysis
AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, acute myeloid leukemia, and amyloidosis. Key focus areas include approved therapies like EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax), as well as investigational compounds such as etentamig (ABBV-383) and pivekimab sunirine-pvzy. Significant efficacy data was presented for epcoritamab in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. A subgroup analysis of the Phase 3 EPCORE FL-1 trial showed numerically higher overall response rates (ORR) with the combination therapy compared to standard care across various risk subgroups, including patients with higher-risk disease features. The data also demonstrated consistent safety profiles across these subgroups with no new safety signals identified. In relapsed or refractory large B-cell lymphoma, epcoritamab monotherapy showed a statistically significant improvement in progression-free survival versus investigator's choice of chemoimmunotherapy. The study reported a 24-month progression-free survival rate of 30% for the epcoritamab arm compared to 13% for the control group. However, the study did not demonstrate a statistically significant improvement in overall survival, though there was no OS detriment per pre-specified criteria. Additional data covers venetoclax-based therapies in chronic lymphocytic leukemia based on genetic biomarkers, real-world management practices for acute myeloid leukemia, and efficacy of etentamig in multiple myeloma and amyloidosis. The company emphasized its commitment to pioneering innovative solutions to elevate standards of care and address pressing challenges in treating blood cancers through a robust pipeline of investigational and approved medicines.